Showing 1 - 10 of 286
This paper is a re-examination of the relationship between research and development (R&D) activity and total factor productivity (TFP) at the industry level during the period extending from the early 1960's to the mid-1970's. The data base consists of NSF data on applied R&D expenditures by...
Persistent link: https://www.econbiz.de/10013230811
In this paper we investigate the incidence of measurement errors in two independent estimates of long-term price change, within the framework of "multiple indicators" models of price measurement. We develop estimates of the measurement-error variances associated with both the Producer Price...
Persistent link: https://www.econbiz.de/10013310591
Persistent link: https://www.econbiz.de/10001674274
Longitudinal, disease-level data are used to analyze the impact of pharmaceutical innovation on longevity (mean age at death), hospital utilization, and medical expenditure in Greece during the period 1995 - 2010. The estimates indicate that pharmaceutical innovation increased mean age at death...
Persistent link: https://www.econbiz.de/10010473542
Dean Baker and Adriane Fugh-Berman have published a critique of a study I performed in 2007, entitled "Why has longevity increased more in some states than in others?ʺ One of the conclusions I drew from that study was that medical innovation accounts for a substantial portion of recent...
Persistent link: https://www.econbiz.de/10003861794
There are two types of prescription drug cost offsets. The first type of cost offset - from prescription drug use - is primarily about the effect of changes in drug quantity (e.g. due to changes in out-of-pocket drug costs) on other medical costs. The second type of cost offset - the cost offset...
Persistent link: https://www.econbiz.de/10011987056
I investigate the contribution of pharmaceutical innovation to recent longevity growth in Germany and France. First, I examine the effect of the vintage of prescription drugs (and other variables) on the life expectancy and age-adjusted mortality rates of residents of Germany, using...
Persistent link: https://www.econbiz.de/10003977959
We update and extend our previous study of the effect of drug age -- years since FDA approval -- on total medical expenditure, in several respects. The estimates indicate that, in the entire population, a reduction in the age of drugs utilized reduces non-drug expenditure 7.2 times as much as it...
Persistent link: https://www.econbiz.de/10012469718
This paper reviews the literature on the relationship of economic growth to the education levels of the labor force. The emphasis is on Ben-Porath's contribution to some of the issues in this field: the endogeneity of schooling, the role of the public sector as an `absorber' of educated labor,...
Persistent link: https://www.econbiz.de/10012473438
This note reviews the history of the 'residual,' from its earliest articulation in Copeland (1937) to its codification in Solow (1957), describing the various earlier contributions by Tinbergen, Stigler, Schmookler, Fabricant, Kendrick, Abramovitz and others
Persistent link: https://www.econbiz.de/10012473521